REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in September: Cantor Global Healthcare ConferencePresentation Date: Wednesday, September 3, 2025 at 1:00 PM ETPresentation Format: Fireside ChatWebcast: Here Wells Fargo Healthcare ConferencePresentation Date: Thursday, September ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno (SLNO) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Soleno and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential cla ...

NEW YORK, Aug. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Soleno and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On August 15, 2025, ...

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. (“Soleno” or the “Company”) (NASDAQ: SLNO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Soleno and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On Augu ...

Core Points - Holzer & Holzer, LLC is investigating Soleno Therapeutics, Inc. for potential violations of federal securities laws following a report by Scorpion Capital that questioned the credibility of the company's phase 3 clinical trials for its drug VYKAT™ XR [1] - The report from Scorpion Capital highlighted numerous problems with the clinical trials and withdrawal studies, leading to a decline in Soleno Therapeutics' stock price [1] Company Overview - Soleno Therapeutics, Inc. is publicly traded on NASDAQ under the ticker SLNO and is focused on developing treatments, including VYKAT™ XR [1] - The company is currently facing scrutiny regarding its compliance with securities laws due to allegations of issues in its clinical trial processes [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in securities litigation and has a history of representing shareholders in class action lawsuits [3] - The firm has been recognized as a top-rated securities litigation law firm for multiple years and has recovered significant amounts for investors affected by corporate misconduct [3]

Core Viewpoint - Soleno Therapeutics, Inc. (SLNO) is experiencing significant selling pressure, with a 21.7% decline over the past four weeks, but is now positioned for a potential trend reversal due to being in oversold territory and positive earnings expectations from Wall Street analysts [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a momentum oscillator that indicates whether a stock is oversold, with readings below 30 typically signaling this condition [2]. - SLNO's current RSI reading is 26.7, suggesting that the heavy selling pressure may be exhausting itself, indicating a potential trend reversal [5]. Group 2: Fundamental Indicators - There is a strong consensus among sell-side analysts that SLNO will report better earnings than previously predicted, with a 46.7% increase in the consensus EPS estimate over the last 30 days [7]. - The upward trend in earnings estimate revisions is generally associated with price appreciation in the near term [7]. Group 3: Analyst Ratings - SLNO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8].

Core Viewpoint - Soleno Therapeutics, Inc. has faced a significant decline in share price following a critical report by Scorpion Capital, which raised serious concerns about the safety and commercial viability of its drug VYKAT™ XR [1][4]. Company Overview - Soleno Therapeutics is focused on developing treatments for Prader-Willi syndrome, with its primary product being VYKAT™ XR, a once-daily oral tablet aimed at treating hyperphagia, a condition associated with the syndrome [2][4]. Investigation Details - Hagens Berman has initiated an investigation into Soleno to determine if the company misled investors regarding the safety and commercial prospects of VYKAT™ XR [2][3][6]. - The investigation will scrutinize Soleno's statements about the drug's safety and its commercial potential, particularly in light of recent adverse reports [3][6]. Critical Report Findings - Scorpion Capital's report highlighted a concerning trend of children being hospitalized for potential heart failure after using VYKAT™ XR, suggesting that the drug may face market withdrawal or a significant drop in new prescriptions [4][5]. - The report characterized Soleno as a "one-trick pony," emphasizing the lack of other meaningful assets or scientific programs, and warned of the company's potential demise if VYKAT™ XR fails, especially with its core patent expiring in 2026 [4][5]. Concerns Raised - Scorpion Capital criticized Soleno's launch metrics as misleading and pointed to a controversial physician involved in key trials, suggesting potential issues with data integrity and scientific standards [5][6]. - Allegations were made regarding irregularities in the physician's co-authored papers, which could undermine the validity of Soleno's trials and FDA submissions [5].

Group 1 - Soleno Therapeutics, Inc. (SLNO) shares have increased by 1% over the past four weeks, closing at $82.35, with a mean price target of $117.88 indicating a potential upside of 43.2% [1] - The mean estimate consists of eight short-term price targets with a standard deviation of $13.62, where the lowest estimate is $100.00 (21.4% increase) and the highest is $145.00 (76.1% increase) [2] - Analysts show a strong consensus that SLNO will report better earnings than previously estimated, which is a positive indicator for potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for SLNO's current year earnings has risen by 56.7% over the past month, with five estimates increasing and no negative revisions [12] - SLNO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential for near-term upside [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a good guide for potential price movement [14]

Core Viewpoint - The article emphasizes the importance of confirming the sustainability of stock trends for successful short-term investing, highlighting that price movements should be supported by strong fundamentals and positive earnings estimates [1][2]. Group 1: Stock Performance - Soleno Therapeutics, Inc. (SLNO) has shown a solid price increase of 9.8% over the past 12 weeks, indicating investor confidence in its potential upside [4]. - SLNO has maintained a price increase of 1% over the past four weeks, suggesting that the upward trend is still intact [5]. - The stock is currently trading at 83.7% of its 52-week high-low range, indicating a potential breakout opportunity [5]. Group 2: Fundamental Strength - SLNO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. - The Zacks Rank system has a strong historical performance, with Zacks Rank 1 stocks averaging an annual return of +25% since 1988 [7]. Group 3: Investment Strategy - The "Recent Price Strength" screen is a useful tool for identifying stocks like SLNO that are on an uptrend supported by strong fundamentals [3]. - Investors are encouraged to explore over 45 Zacks Premium Screens tailored to different investing styles to find potential winning stocks [8].

Financial Performance - Soleno Therapeutics reported a quarterly loss of $0.09 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.53, and an improvement from a loss of $0.57 per share a year ago, representing an earnings surprise of +83.02% [1] - The company posted revenues of $32.66 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 1.58%, compared to zero revenues a year ago [2] Stock Performance - Soleno Therapeutics shares have increased approximately 81.6% since the beginning of the year, outperforming the S&P 500's gain of 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.49 on revenues of $24.62 million, and for the current fiscal year, it is -$2.13 on revenues of $122.75 million [7] Industry Outlook - The Medical - Drugs industry, to which Soleno Therapeutics belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the company's stock may continue to perform well based on these revisions [5][6]